[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, Niraparib is indeed effective for ovarian cancer. Document [0] mentions that Niraparib is approved for use in the maintenance treatment of ovarian cancer regardless of biomarker status. Document [2] highlights the role of Niraparib in improving outcomes in all subgroups of ovarian cancer patients, leading to its approval by the US FDA. Document [5] states that Niraparib significantly prolongs progression-free survival and is an effective option for the maintenance treatment of recurrent ovarian cancer. Document [12] also supports the efficacy of Niraparib in the treatment and maintenance of relapsed ovarian cancer. Overall, the evidence from these documents suggests that Niraparib is effective for ovarian cancer.\", \"answer_choice\": \"A\"}"
]